New Diagnostics Working Group

New Diagnostics Working Group E-news
December 2014

New scientific articles

**A simple, single triplex PCR of IS6110, IS1081 and 23S ribosomal DNA targets, developed for rapid detection and discrimination of mycobacterium from clinical samples.**

**Evaluation of the Cobas TagMan MTB Test for the Detection of Mycobacterium tuberculosis Complex According to Acid-Fast Bacilli Smear Grades in Respiratory Specimens.**

**Discrimination between active and latent tuberculosis based on the ratio of antigen-specific to mitogen-induced IP-10 production.**

**High-throughput MIRU-VNTR genotyping for Mycobacterium tuberculosis epidemiological studies.**

**Impact of Xpert MTB/RIF for TB Diagnosis in a Primary Care Clinic with High TB and HIV Prevalence in South Africa: A Pragmatic Randomised Trial.**

**Loop-mediated isothermal amplification assay for rapid and sensitive diagnosis of tuberculosis.**

**High positive predictive value of Xpert in a low rifampicin resistance prevalence setting.**

**IP-10 is an accurate biomarker for the diagnosis of tuberculosis in children.**

**CFP10 and ESAT6 aptamers as effective Mycobacterial antigen diagnostic reagents.**

**Microscopic observation drug susceptibility assay for the diagnosis of TB and MDR-TB in HIV-infected patients: a systematic review and meta-analysis.**

Other Publications

**The End TB Strategy: a global rally**

**Pre-entry screening programmes for tuberculosis in migrants to low-incidence countries: a systematic review and meta-analysis.**

**Pre-entry, post-entry, or no tuberculosis screening?**
Tuberculosis control: hard questions.  

Tuberculosis control: hard questions - Authors' reply.  
Khan MS, Coker RJ. Lancet. 2014

Tuberculosis in pregnancy: an estimate of the global burden of disease  

Key Publications

Report of the joint ECDC and WHO review of the national tuberculosis programme in Bulgaria  
ECDC

News

Global consultation on research for tuberculosis elimination  
Sanofi Receives FDA Approval of Priftin® (rifapentine) Tablets for the Treatment of Latent Tuberculosis Infection